solute carrier family 35 member B3Genealiases: C6orf196 · CGI-19 · PAPST2
Q-omics provides the consensus-scored SLC35B3 profile across patient tissues and cancer cell-line models. SLC35B3 expression is associated with patient survival in 26 of 34 cancer types, with the highest sampling consensus in UVM. Among the 18 cancer types available for tumor–normal comparison, SLC35B3 is differentially expressed in 13, with the highest sampling consensus in THCA. Additionally, SLC35B3 RNA expression shows 19,952 significant gene co-expression associations, with the highest sampling consensus in ACC. Together, these results highlight UVM, THCA, and ACC as cancer lineages where SLC35B3 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for SLC35B3 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes SLC35B3 survival associations across molecular data types. SLC35B3 RNA expression shows survival associations in the most cancer types (26), followed by mutation status (3) and mass-spec protein abundance (6). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible SLC35B3 RNA expression–survival associations across cancer types. High SLC35B3 expression shows unfavorable associations in UVM, ACC and LGG, but favorable associations in THYM, READ and KIRC. The UVM Kaplan–Meier curve shows clear separation, with the high-expression group declining faster, consistent with the unfavorable association (log-rank p < 0.001). Together, the overview and detailed table identify UVM as the clearest survival context for SLC35B3 RNA expression.
This table summarizes SLC35B3 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 13, while mass-spec protein shows differences in 6. The strongest signals are observed in THCA for RNA and LUAD for protein.
This table ranks reproducible tumor–normal expression differences for SLC35B3. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. SLC35B3 shows lower tumor expression in THCA and KICH and higher tumor expression in STAD, LUAD, HNSC and BRCA. The THCA box plot shows higher SLC35B3 RNA expression in normal versus tumor tissue (log2 FC = −1.085, t-test p < 0.001).
This table shows molecular features associated with SLC35B3 in patient tissues and cancer cell lines. In patient samples, SLC35B3 shows the broadest associations at the RNA and protein expression levels, with ACC recurring as the lineage with the largest associated feature set. In cancer cell lines, SLC35B3 RNA and mutation anchors are most strongly linked to RNA-expression features, especially in BLOOD_Myeloma, while CRISPR and shRNA rows add functional-dependency signals in PANCREAS and BLOOD_Lymphoma.
